Example: Heart Attack

Clinical Trials on Neisseriaceae Infections

Total 508 results

NCT00091728

Terminated

Hormonal Contraception and Risk of Chlamydia and Gonorrhea

Conditions: Chlamydia Infection; Neisseriaceae Infection
NCT04714229

Active, not recruiting

Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

Conditions: Infection, Meningococcal
NCT04502693

Recruiting

Study to Assess Effectiveness of GlaxoSmithKline's (GSK's) Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults.

Conditions: Infections, Meningococcal
NCT04318548

Recruiting

Study to Assess the Immunogenicity and Safety of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Conditions: Infections, Meningococcal
NCT04184336

Recruiting

Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada

Conditions: Invasive Meningococcal Disease
NCT03652610

Completed

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

Conditions: Infections, Meningococcal
NCT03621670

Recruiting

GlaxoSmithKline's (GSK) Safety and Immunogenicity Study of GSK Meningococcal Group B and 13-valent Pneumococcal Vaccines Administered Together With Routine Infant Vaccines in Healthy Infants

Conditions: Infections, Meningococcal
NCT04239430

Not yet recruiting

Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study

Conditions: HIV/AIDS; Meningococcal Disease
NCT02986854

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Conditions: Infections, Meningococcal
NCT02946385

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Conditions: Infections, Meningococcal
NCT02640677

Completed

Safety of 4CMenB Exposure During Pregnancy

Conditions: Infections, Meningococcal
NCT02639351

Completed

Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

Conditions: Infections, Meningococcal
NCT02446743

Completed

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Conditions: Infections, Meningococcal
NCT02446691

Completed

Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

Conditions: Infections, Meningococcal
NCT02212457

Completed

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Conditions: Infections, Meningococcal
NCT02106390

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Conditions: Infections, Meningococcal
NCT02451514

Completed

A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

Conditions: Meningococcal Disease; Infections, Meningococcal
NCT01962207

Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Conditions: Infections, Meningococcal
NCT01939158

Completed

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Conditions: Infections, Meningococcal
NCT01934140

Completed

Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

Conditions: Infections, Meningococcal
NCT01900899

Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Conditions: Infections, Meningococcal
NCT02287688

Completed

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study

Conditions: Meningococcal Disease; Infections, Meningococcal
NCT01755689

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Conditions: Infections, Meningococcal
NCT01808365

Completed

N. Meningitidis Carriage Study

Conditions: Infections, Meningococcal
NCT01777308

Completed

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

Conditions: Infections, Meningococcal